anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 528 outpatient and hospitalized adults with clinically and radiologically determined mild to severe community-acquired pneumonia were evaluated in a double-blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg, IV or orally, every day for five days or levofloxacin 500 mg IV or orally, every day for 10 days.

  


Clinical success rates (cure plus improvement) in the clinically evaluable population were 90.9% in the levofloxacin 750 mg group and 91.1% in the levofloxacin 500 mg group. The 95% CI for the difference of response rates (levofloxacin 750 minus levofloxacin 500) was [-5.9, 5.4]. In the clinically evaluable population (31 to 38 days after enrollment) pneumonia was observed in 7 out of 151 patients in the levofloxacin 750 mg group and 2 out of 147 patients in the levofloxacin 500 mg group. Given the small numbers observed, the significance of this finding cannot be determined statistically. The microbiological efficacy of the 5-day regimen was documented for infections listed in Table 13.
This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
The invention discloses an application of a chlorogenic acid nano powder inhalation in a medicine for treating acute lung injury. The chlorogenic acid nano powder inhalation is prepared with a chlorogenic acid nano medicine delivery system selected from the dosage forms of lipidosomes, nano-particles, nano-emulsions and micro-emulsions with or without addition of an auxiliary material. The medicine delivery system is dried into solid powder and is then mixed with a carrier to prepare the chlorogenic acid nano powder inhalation. The nano powder inhalation is stable, is easy to enter the deep parts of lung tissue, allows targeted positioning, is convenient to carry and use and has advantages on treatment of the acute lung injury. The chlorogenic acid nano powder inhalation is used for treating acute lung injuries caused by infection, shock, smoking, wound, poisoning, inhalation of simulative gas, irradiation, high-oxygen and low-oxygen atmospheres and the like. The simulative gas herein comprises phosgene, diphosgene, triphosgene, chlorine, nitrogen oxides, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.
Color changing cosmetic adhesives for adhering a cosmetic i tem. The color changing cosmetic adhesives include an adhesive formulation and a dye formulation. The dye formulation is distributed within the adhesive formulation. The dye formulation is configured to impart a first color to the adhesive formulation while the adhesive formulation is stored in a container. The dye formulation is configured to impart a second color to the adhesive formulation after the adhesive formulation is applied to skin. In some examples, the color changing cosmetic adhesive includes a preservative formulation.
In addition to its health benefits, mindfulness has been theorized in classical contemplative frameworks to elicit self-transcendent experiences as a means of promoting universal love and compassion. Increasing feelings of love may be especially clinically relevant for the treatment of opioid misuse, in that addictive use of opioids dysregulates neurobiological processes implicated in the experience of love. Here we tested these hypotheses in a secondary analysis (n = 187) of data from a randomized clinical trial of Mindfulness-Oriented Recovery Enhancement (MORE) versus supportive psychotherapy for comorbid opioid misuse and chronic pain. At pre- and post-treatment, participants completed a measure of state self-transcendence immediately following a laboratory-based mindfulness task. Through 9-month follow-up, we assessed changes in universal love and opioid misuse. Participants also completed ecological momentary assessments of opioid craving during the 8-week study interventions and for the following month. Compared to supportive psychotherapy, participants in MORE reported significantly greater increases in mindfulness-induced self-transcendence, which mediated the effect of MORE on increased feelings of universal love. In turn, increases in universal love significantly predicted decreased opioid craving and lower odds opioid misuse through 1- and 9-month follow-ups, respectively. Findings suggest mindfulness-induced self-transcendence may promote feelings of universal love, with possible downstream benefits on reducing addictive behavior.
The present invention provides a Chinese patent medicine used for treating eyeground pathological changes of diabetes. The present invention is the Chinese patent medicine prepared from Chinese herbal medicines of glossy privet fruit, barbary wolfberry fruit, papermulberry fruit, semen cassiae, motherwort fruit, ophiopogon root and feverfew. The medicine has the effect of nourishing the liver, invigorating the kidney, supplementing qi, activating blood circulation, removing liver-fire for improving eyesight, etc. The present invention is suitable for treating the concurrent eyeground pathological changes of diabetes. The present invention has the characteristics of unique formulation, reasonable medicinal proportion, both manifestation and root cause of disease treatment, outstanding curative effect, obvious effect, low cost, convenient administration and no side effect. The present invention is the new Chinese patent medicine used for treating the eyeground pathological changes of diabetes.
The invention discloses a method for preparing a Wuyi Mountain rock tea extract. The method comprises the following steps of: (1) extracting the Wuyi Mountain rock tea by using ethanol aqueous solution; and (2) separating the substance obtained in the step (1) by using a macroporous resin column and collecting a fraction with the volume ratio of developing agent dichloromethane to methanol to water of 8:3:1 and an Rf value of 0.16 to 0.45 during detection by silica gel thin layer chromatography so as to prepare the extract. The method can also comprise the following steps of: performing chromatographic separation on the substance obtained in the step (2) by using a silica gel column; and collecting one or more of three fractions with the volume ratio of the developing agent dichloromethane to the methanol to the water of 8:3:1 and the Rf value of 0.44 during detection by silica gel thin layer chromatography. The invention also relates to the Wuyi Mountain rock tea extract and application thereof. The Wuyi Mountain rock tea extract has stable properties and high water solubility. Compared with the conventional tea polyphenol aglycon, the Wuyi Mountain rock tea extract has more stable properties and higher activity.
A new method for labeling proteins with 99m-technetium: (1) Start with any volume of technetium (pertechnetate and saline) solution and add 0.1 ml of stannous solution (stannous fluoride-acetate solution) per 15-20 ml of saline. The stannous ions will reduce the pertechnetate to technetium IV. (2) Pour the solution onto a sterile Sephadex G-25 column, The reduced technetium (Tc-IV) will bind to the very top layer of Sephadex. (3) Wash the column with saline solution to remove any free pertechnetate or unusual species of technetium. (4) Add the protein in the minimum volume of water to the top of the Sephadex column. Wait 30 minutes. During this waiting period ligand exchange will occur and the technetium will become bound to the protein, but only to those sites on the protein that form a stronger ligand bond than the Sephadex. This means that the only product that will be formed will be technetium strongly bound to proteins. (5) Wash the labeled protein through the column by adding 1 cc of human serum albumin solution diluted 50/50 with ACD. (6) When this has all soaked into the column, add 5 cc of saline, which means that since the volume of the column is 5 cc there will be 6 cc of eluate. The last (or 6th) cc will contain the Tc-labeled human serum albumin. The impurities will remain on the column.
The invention provides cough-relieving tea and a preparation method thereof. Based on mass percentage, the cough-relieving tea comprises 8 to 12 grams of Cyperus rotundus, 3 to 7 grams of couchgrass root and 2 to 4 grams of lily, wherein the Cyperus rotundus serves as a main material; and the couchgrass root and the lily serve as auxiliary materials. The cough-relieving tea provided by the invention has obvious effect of reducing phlegm, clearing and moistening. After the cough-relieving tea is taken for one to two times, phlegm in the throat is obviously eliminated and response is quick. The cough symptom can be obviously relieved on the next day after the cough-relieving tea is taken. The cough-relieving product with quick response and safety brings a good choice to cough patients.
1. Technical Result Increase in delivery of a bioactive agent to the respiratory tract.           2. Essence Perforated microparticles are receved by dispersing liquid mixture comprising a bioactive agent and blowing agent is dispersed and drying the obtained dispersed drops, which results in production of perforated microparticles having the mean aerodynamic diameter 0,5-5 mkm. The obtained Perforated microparticles may be used in the form of dry powders or in the form of stabilized dispersions, an inhalation device preferably comprising a dry powder inhaler, metered dose inhaler or a nebulizer.           3. Field of Application Medicine.               Tables: 10
The safety and efficacy of conversion from calcineurin inhibitors to sirolimus in maintenance renal transplant population have not been established [see Clinical Studies (14.4)]. In a study evaluating the safety and efficacy of conversion from calcineurin inhibitors to sirolimus (initial target sirolimus concentrations of 12 to 20 ng/mL, and then 8 to 20 ng/mL, by chromatographic assay) in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n = 87) with a baseline glomerular filtration rate of less than 40 mL/min. There was a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death, in this stratum of the sirolimus treatment arm.

The subset of patients with a baseline glomerular filtration rate of less than 40 mL/min had 2 years of follow-up after randomization. In this population, the rate of pneumonia was 25.9% (15/58) versus 13.8% (4/29), graft loss (excluding death with functioning graft loss) was 22.4% (13/58) versus 31% (9/29), and death was 15.5% (9/58) versus 3.4% (1/29) in the sirolimus conversion group and CNI continuation group, respectively.

In the subset of patients with a baseline glomerular filtration rate of greater than 40 mL/min, there was no benefit associated with conversion with regard to improvement in renal function and a greater incidence of proteinuria in the sirolimus conversion arm.

Overall in this study, a 5-fold increase in the reports of tuberculosis among sirolimus 2% (11/551) and comparator 0.4% (1/273) treatment groups was observed with 2:1 randomization scheme.

In a second study evaluating the safety and efficacy of conversion from tacrolimus to sirolimus 3 to 5 months post-kidney transplant, a higher rate of adverse events, discontinuations due to adverse events, acute rejection, and new onset diabetes mellitus was observed following conversion to sirolimus. There was also no benefit with respect to renal function and a greater incidence of proteinuria was observed after conversion to sirolimus [see Clinical Studies (14.4)].
BACKGROUND: Ferrum phosphoricum (FP) has been used by traditional medicine practitioners for various ailments since ancient times. However, scientific evidence on the safety of FP is still unavailable. Thus, the current study aimed to investigate the acute and sub-acute oral toxicity of homeopathic FP in experimental rats.
METHODS: In an acute toxicity investigation, a single dose of 2,000 µL/kg of FP 6c, 30c and 200c was administered to female Wistar rats, which were monitored for up to 14 days according to the Organization for Economic Cooperation and Development (OECD) guideline 423. For a sub-acute toxicity study, FP 6c, 30c and 200c (200 µL/kg) were administered to male and female rats for 28 days as per the OECD guideline 407. All the animals were observed for mortality, clinical signs and body weight during the study. At the end of the experiment, hematological, biochemical and histopathological assessments were performed.
RESULTS: During the acute toxicity study, no mortality was observed in rats administered with FP, and thus the median lethal dose (LD50) was identified as >2,000 µL/kg. In the sub-acute study, no mortality or adverse clinical signs were noticed with FP treatment. Moreover, weekly body weight gain was normal. Hematological and biochemical investigations revealed no abnormalities. Furthermore, histological analysis of FP-treated rats' vital organs revealed no pathological changes.
CONCLUSION: Overall, our findings imply that FP 6c, 30c and 200c potencies are safe and do not cause toxicity when given orally to Wistar albino rats for an extended period at a dose of 200 µL/kg.
We will conduct a 4.5-year community-based RCT to study the impact of intervention approaches (small-group video discussion vs. single video mode) on mammography used among Chinese immigrant women. The small-group video discussion will be led by trained Chinese community health educators and trained bilingual research staff using a standardized structured protocol at all sites. In the single video mode, we will mail the intervention materials to women to view and/or read at home. We will recruit 974 Chinese women through our strong and well-established Chinese community partnerships in the metropolitan areas of Washington, DC (Lead PI: Dr. Judy Wang, Georgetown University-GU), New York (Site PI: Dr. Grace Ma at Temple University), and southern California (Site PI: Dr. Annette Maxwell, University of California, Los Angeles-UCLA). Participants' eligibility are listed under "eligibility criteria". We will not enroll US-born Chinese women as they are least likely to face cultural and language barriers to mammography and less likely to engage in our small-group discussion, which will be conducted in Chinese languages. Also, we will not enroll short-term visitors as our study involves four interviews over a 2-year period.
Subjects start with no money in an account, but they earn a fixed amount with each response. In this arm, each adult report is worth $3.17 so an adult subject can earn up to $200 if he/she responds to all surveys. If an adult completes at least 75% of the reports, he/she will receive an $100 bonus for a total maximum of $300. In this arm, each child report is worth 0.52 cents so a child subject can earn up to $33 if he/she responds to all surveys. If a child completes at least 75% of the reports, he/she will receive a $17 bonus for a total maximum of $50.
This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
IL17 is required for the initiation and progression of pancreatic cancer, particularly in the context of inflammation, as previously shown by genetic and pharmacological approaches. However, the cellular compartment and downstream molecular mediators of IL17-mediated pancreatic tumorigenesis have not been fully identified. This study examined the cellular compartment required by generating transgenic animals with IL17 receptor A (IL17RA), which was genetically deleted from either the pancreatic epithelial compartment or the hematopoietic compartment via generation of IL17RA-deficient (IL17-RA-/-) bone marrow chimeras, in the context of embryonically activated or inducible Kras. Deletion of IL17RA from the pancreatic epithelial compartment, but not from hematopoietic compartment, resulted in delayed initiation and progression of premalignant lesions and increased infiltration of CD8+ cytotoxic T cells to the tumor microenvironment. Absence of IL17RA in the pancreatic compartment affected transcriptional profiles of epithelial cells, modulating stemness, and immunological pathways. B7-H4, a known inhibitor of T-cell activation encoded by the gene Vtcn1, was the checkpoint molecule most upregulated via IL17 early during pancreatic tumorigenesis, and its genetic deletion delayed the development of pancreatic premalignant lesions and reduced immunosuppression. Thus, our data reveal that pancreatic epithelial IL17RA promotes pancreatic tumorigenesis by reprogramming the immune pancreatic landscape, which is partially orchestrated by regulation of B7-H4. Our findings provide the foundation of the mechanisms triggered by IL17 to mediate pancreatic tumorigenesis and reveal the avenues for early pancreatic cancer immune interception. See related Spotlight by Lee and Pasca di Magliano, p. 1130.
BACKGROUND: The chronic inflammatory immune response is a significant factor in the pathogenesis of benign gynecological diseases. The systemic immunoinflammatory index (SII) and the platelet-to-lymphocyte ratio (PLR) are commonly available biomarkers of inflammation. However, evidence of the relationship between SII and PLR in patients with adenomyosis is limited. This study aimed to investigate the relationship between SII and PLR in patients with adenomyosis.
METHODS: This cross-sectional study included 483 patients with adenomyosis who were first diagnosed at our institution between January 2019 and December 2021. Basic patient clinical information and inflammatory factors were collected for univariate analysis, smoothed curve fitting, and multivariate segmented linear regression.
RESULTS: The results of the univariate analysis showed a significant positive correlation between PLR levels and SII (P < 0.001). In addition, a nonlinear relationship between PLR and SII was tested using a smoothed curve fit after adjusting for potential confounders. Multiple segmented linear regression models showed a significant relationship between SII and PLR in both SII < 1,326.47 (β 0.14, 95% CI: 0.12, 0.16; P < 0.0001) and >1,326.47 (β 0.02, 95% CI: -0.01, 0.05; P = 0.2461).
CONCLUSIONS: In conclusion, this study showed a nonlinear relationship between SII and PLR in patients with uterine adenomyosis. An increase in serum PLR levels correlates with an increase in SII before SII levels reach an inflection point.
Rice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
Increases in liver enzymes have been observed with SIGNIFOR LAR. In all Phase 3 acromegaly studies and across all doses, alanine aminostransferase (ALT) or aspartate aminotransferase (AST) elevations greater than 3 times the upper limit of normal (ULN) were observed in 4% of acromegaly patients and ALT or AST elevations greater than 5 times the ULN were observed in 1% of acromegaly patients treated with SIGNIFOR LAR.

In the Phase 3 Cushing's disease study and across all doses, ALT or AST elevations greater than 3 times the ULN were observed in 14% of Cushing's disease patients and ALT or AST elevations greater than 5 times the ULN were observed in 5% of Cushing's disease patients treated with SIGNIFOR LAR.

Assessment of liver function is recommended prior to treatment with SIGNIFOR LAR , and after the first 2- to 3 weeks, then monthly for 3 months. Thereafter, liver function should be monitored as clinically indicated. Patients who develop increased transaminase levels, should be monitored until values return to pre-treatment levels. Treatment with SIGNIFOR LAR should be discontinued if signs or symptoms suggestive of clinically significant liver impairment develop. Following discontinuation of treatment with SIGNIFOR LAR, patients should be monitored until resolution. Treatment should not be restarted, if the liver function abnormalities are suspected to be related to SIGNIFOR LAR.
Vaccination against human papillomavirus (HPV) is changing the performance of cytology as a cervical screening test, but its effect on HPV testing is unclear. We review the effect of HPV16/18 vaccination on the epidemiology and the detection of HPV infections and high-grade cervical lesions (CIN2+) to evaluate the likely direction of changes in HPV test accuracy. The reduction in HPV16/18 infections and cross-protection against certain non-16/18 high-risk genotypes, most notably 31, 33, and/or 45, will likely increase the test's specificity but decrease its positive predictive value (PPV) for CIN2+. Post-vaccination viral unmasking of non-16/18 genotypes due to fewer HPV16 co-infections might reduce the specificity and the PPV for CIN2+. Post-vaccination clinical unmasking exposing a higher frequency of CIN2+ related to non-16/18 high-risk genotypes is likely to increase the specificity and the PPV of HPV tests. The effect of HPV16/18 vaccination on HPV test sensitivity is difficult to predict based on these changes alone. Programmes relying on HPV detection for primary screening should monitor the frequency of false-positive and false-negative tests in vaccinated (younger) vs. unvaccinated (older) cohorts, to assess the outcomes and performance of their service.
Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18-month follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three-fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow-up. In conclusion, our real-world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.
PURPOSE: A system for linking electronic medical affair records based on wireless recognition is provided to track a location of a patient with a tag and associate the tracked location with EMR using an RTLS(Real Time Locating System), thereby sensing location information of the patient in real time. CONSTITUTION: A receiver(21) receives patient information and tag information mapped on the patient information. The receiver receives location information of a tag which the patient has. A location information extractor(22) extracts location information of each patient. A transmitter transmits the location information. A storage unit(23) stores the location information. The storage unit stores reservation information of a patient.